Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease

by NASDAQ Market News December 7, 2020

NASDAQ Market News
Click here to email author

Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition

ALX Oncology Announces Proposed Public Offering of Common Stock

Ads